{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T16:41:35Z","timestamp":1785688895943,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T00:00:00Z","timestamp":1441670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s13277-015-4018-6","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T23:14:35Z","timestamp":1441667675000},"page":"2127-2136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["14-3-3\u03c3 confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules"],"prefix":"10.1007","volume":"37","author":[{"given":"Kenneth K. Y.","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Tak","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Yuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Y. M.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yu","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai Nar","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K. H.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond W. Y.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,8]]},"reference":[{"key":"4018_CR1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00268-010-0876-7","volume":"35","author":"DK Tong","year":"2011","unstructured":"Tong DK, Law S, Kwong DL, Wei WI, Ng RW, Wong KH. Current management of cervical esophageal cancer. World J Surg. 2011;35:600\u20137.","journal-title":"World J Surg"},{"key":"4018_CR2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.sla.0000086545.45918.ee","volume":"238","author":"S Law","year":"2003","unstructured":"Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339\u201347. discussion 47-8.","journal-title":"Ann Surg"},{"key":"4018_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.yasu.2007.05.007","volume":"41","author":"S Law","year":"2007","unstructured":"Law S, Wong J. The current management of esophageal cancer. Adv Surg. 2007;41:93\u2013119.","journal-title":"Adv Surg"},{"key":"4018_CR4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/bmj.1.6179.1689","volume":"1","author":"CJ Williams","year":"1979","unstructured":"Williams CJ, Whitehouse JM. Cis-platinum: a new anticancer agent. Br Med J. 1979;1:1689\u201391.","journal-title":"Br Med J"},{"key":"4018_CR5","first-page":"54","volume":"36","author":"Y Li","year":"2015","unstructured":"Li Y, Wang X, Li J, Ding W. Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Eur J Gynaecol Oncol. 2015;36:54\u20138.","journal-title":"Eur J Gynaecol Oncol"},{"key":"4018_CR6","doi-asserted-by":"crossref","unstructured":"Du P, Zhang X, Liu H, Chen L. Lentivirus-Mediated RNAi Silencing Targeting ERCC1 Reverses Cisplatin Resistance in Cisplatin-Resistant Ovarian Carcinoma Cell Line. DNA Cell Biol. 2015;in press.","DOI":"10.1089\/dna.2015.2805"},{"key":"4018_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcp.2014.10.013","volume":"93","author":"AK Mishra","year":"2015","unstructured":"Mishra AK, Dormi SS, Turchi AM, Woods DS, Turchi JJ. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochem Pharmacol. 2015;93:25\u201333.","journal-title":"Biochem Pharmacol"},{"key":"4018_CR8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","volume":"16","author":"XC Hu","year":"2015","unstructured":"Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16:436\u201346.","journal-title":"Lancet Oncol"},{"key":"4018_CR9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/carcin\/bgs142","volume":"33","author":"Y Liu","year":"2012","unstructured":"Liu Y, Bernauer AM, Yingling CM, Belinsky SA. HIF1a regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis. 2012;33:1187\u201392.","journal-title":"Carcinogenesis"},{"key":"4018_CR10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ctrv.2014.10.003","volume":"40","author":"S O'Grady","year":"2014","unstructured":"O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev. 2014;40:1161\u201370.","journal-title":"Cancer Treat Rev"},{"key":"4018_CR11","doi-asserted-by":"crossref","unstructured":"Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I et al. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Targets. 2015;1-11.","DOI":"10.1517\/14728222.2015.1043269"},{"key":"4018_CR12","first-page":"267","volume":"18","author":"E Motamedian","year":"2015","unstructured":"Motamedian E, Ghavami G, Sardari S. Investigation on metabolism of cisplatin resistant ovarian cancer using a genome scale metabolic model and microarray data. Iran J Basic Med Sci. 2015;18:267\u201376.","journal-title":"Iran J Basic Med Sci"},{"key":"4018_CR13","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1073\/pnas.0915085107","volume":"107","author":"TH Kang","year":"2010","unstructured":"Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A. 2010;107:4890\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4018_CR14","first-page":"711","volume":"7","author":"B Cao","year":"2015","unstructured":"Cao B, Shi Q, Wang W. Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin. J Thorac Dis. 2015;7:711\u20139.","journal-title":"J Thorac Dis"},{"key":"4018_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/jhg.2011.1","volume":"56","author":"Y Imanaka","year":"2011","unstructured":"Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet. 2011;56:270\u20136.","journal-title":"J Hum Genet"},{"key":"4018_CR16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","volume":"104","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 2011;104:707\u201313.","journal-title":"Br J Cancer"},{"key":"4018_CR17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3892\/or.2014.2981","volume":"31","author":"KT Chan","year":"2014","unstructured":"Chan KT, Choi MY, Lai KK, Tan W, Tung LN, Lam HY, et al. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol Rep. 2014;31:1296\u2013304.","journal-title":"Oncol Rep"},{"key":"4018_CR18","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1038\/onc.2011.580","volume":"31","author":"S Fatima","year":"2012","unstructured":"Fatima S, Lee NP, Tsang FH, Kolligs FT, Ng IO, Poon RT, et al. Dickkopf 4 (DKK4) acts on Wnt\/beta-catenin pathway by influencing beta-catenin in hepatocellular carcinoma. Oncogene. 2012;31:4233\u201344.","journal-title":"Oncogene"},{"key":"4018_CR19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00268-011-1302-5","volume":"36","author":"MK Hui","year":"2012","unstructured":"Hui MK, Chan KW, Luk JM, Lee NP, Chung Y, Cheung LC, et al. Cytoplasmic Forkhead Box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World J Surg. 2012;36:90\u20137.","journal-title":"World J Surg"},{"key":"4018_CR20","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s12032-012-0225-9","volume":"29","author":"MK Hui","year":"2012","unstructured":"Hui MK, Lai KK, Chan KW, Luk JM, Lee NP, Chung Y, et al. Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Med Oncol. 2012;29:3009\u201316.","journal-title":"Med Oncol"},{"key":"4018_CR21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.23143","volume":"50","author":"LX Liu","year":"2009","unstructured":"Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 2009;50:1453\u201363.","journal-title":"Hepatology"},{"key":"4018_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cr.7290291","volume":"15","author":"P Mhawech","year":"2005","unstructured":"Mhawech P. 14-3-3 proteins--an update. Cell Res. 2005;15:228\u201336.","journal-title":"Cell Res"},{"key":"4018_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4048\/jbc.2014.17.3.207","volume":"17","author":"S Ko","year":"2014","unstructured":"Ko S, Kim JY, Jeong J, Lee JE, Yang WI, Jung WH. The role and regulatory mechanism of 14-3-3 sigma in human breast cancer. J Breast Cancer. 2014;17:207\u201318.","journal-title":"J Breast Cancer"},{"key":"4018_CR24","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-03-0510","volume":"10","author":"J Akahira","year":"2004","unstructured":"Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res. 2004;10:2687\u201393.","journal-title":"Clin Cancer Res"},{"key":"4018_CR25","first-page":"5175","volume":"30","author":"H Okumura","year":"2010","unstructured":"Okumura H, Kita Y, Yokomakura N, Uchikado Y, Setoyama T, Sakurai H, et al. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 2010;30:5175\u20139.","journal-title":"Anticancer Res"},{"key":"4018_CR26","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1158\/1078-0432.CCR-04-2207","volume":"11","author":"A Perathoner","year":"2005","unstructured":"Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, et al. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res. 2005;11:3274\u20139.","journal-title":"Clin Cancer Res"},{"key":"4018_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1155\/2010\/470314","volume":"29","author":"G Muhlmann","year":"2010","unstructured":"Muhlmann G, Ofner D, Zitt M, Muller HM, Maier H, Moser P, et al. 14-3-3 sigma and p53 expression in gastric cancer and its clinical applications. Dis Markers. 2010;29:21\u20139.","journal-title":"Dis Markers"},{"key":"4018_CR28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.oraloncology.2008.04.006","volume":"45","author":"K Laimer","year":"2009","unstructured":"Laimer K, Blassnig N, Spizzo G, Kloss F, Rasse M, Obrist P, et al. Prognostic significance of 14-3-3sigma expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2009;45:127\u201334.","journal-title":"Oral Oncol"},{"key":"4018_CR29","first-page":"2009","volume":"29","author":"Z Han","year":"2009","unstructured":"Han Z, Dimas K, Tian X, Wang Y, Hemmi H, Yamada K, et al. 14-3-3sigma-dependent resistance to cisplatin. Anticancer Res. 2009;29:2009\u201314.","journal-title":"Anticancer Res"},{"key":"4018_CR30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/1471-2407-10-598","volume":"10","author":"Z Li","year":"2010","unstructured":"Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, et al. Role of 14-3-3sigma in poor prognosis and in radiation and drug resistance of human pancreatic cancers. BMC Cancer. 2010;10:598.","journal-title":"BMC Cancer"},{"key":"4018_CR31","first-page":"119","volume":"2010","author":"Y Liu","year":"1799","unstructured":"Liu Y, Prasad R, Wilson SH. HMGB1: roles in base excision repair and related function. Biochim Biophys Acta. 1799;2010:119\u201330.","journal-title":"Biochim Biophys Acta"},{"key":"4018_CR32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tibs.2011.12.002","volume":"37","author":"Y Liu","year":"2012","unstructured":"Liu Y, Wilson SH. DNA base excision repair: a mechanism of trinucleotide repeat expansion. Trends Biochem Sci. 2012;37:162\u201372.","journal-title":"Trends Biochem Sci"},{"key":"4018_CR33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/978-0-387-09599-8_4","volume":"637","author":"U Camenisch","year":"2008","unstructured":"Camenisch U, Nageli H. XPA gene, its product and biological roles. Adv Exp Med Biol. 2008;637:28\u201338.","journal-title":"Adv Exp Med Biol"},{"key":"4018_CR34","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00018-015-1859-5","volume":"72","author":"S Alekseev","year":"2015","unstructured":"Alekseev S, Coin F. Orchestral maneuvers at the damaged sites in nucleotide excision repair. Cell Mol Life Sci. 2015;72:2177\u201386.","journal-title":"Cell Mol Life Sci"},{"key":"4018_CR35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3892\/ijo.2014.2390","volume":"45","author":"F Lu","year":"2014","unstructured":"Lu F, Zhang J, Ji M, Li P, Du Y, Wang H, et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 2014;45:383\u201392.","journal-title":"Int J Oncol"},{"key":"4018_CR36","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1007\/s13277-014-1797-0","volume":"35","author":"X Li","year":"2014","unstructured":"Li X, Wang S, Chen Y, Liu G, Yang X. miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biol. 2014;35:6021\u20138.","journal-title":"Tumour Biol"},{"key":"4018_CR37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1074\/mcp.M500021-MCP200","volume":"4","author":"A Benzinger","year":"2005","unstructured":"Benzinger A, Muster N, Koch HB, Yates 3rd JR, Hermeking H. Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics. 2005;4:785\u201395.","journal-title":"Mol Cell Proteomics"},{"key":"4018_CR38","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1582-4934.2011.01321.x","volume":"15","author":"A Clocchiatti","year":"2011","unstructured":"Clocchiatti A, Florean C, Brancolini C. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. J Cell Mol Med. 2011;15:1833\u201346.","journal-title":"J Cell Mol Med"},{"key":"4018_CR39","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1021\/cb1000444","volume":"5","author":"TM Neher","year":"2010","unstructured":"Neher TM, Shuck SC, Liu JY, Zhang JT, Turchi JJ. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening. ACS Chem Biol. 2010;5:953\u201365.","journal-title":"ACS Chem Biol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-4018-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4018-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T02:49:19Z","timestamp":1599533359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-4018-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-4018-6","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,8]]}}}